Invitrogen™ IL5RA Polyclonal Antibody

Description

Recommended positive controls: human blood-derived granulocytes. The Neutralization Dose50 (ND50) for anti-human IL5RA is approximately 1-3 μg/mL in the presence of 0.5 ng/mL of recombinant human IL-5 using the human TF-1 cell line. The ND50 is the concentration of antibody required to yield one-half maximal inhibition of the cell surface IL5RA mediated IL5 response on a responsive cell line, at a specific IL5 concentration. The exact concentration of antibody required to neutralize the human cell surface IL5RA mediated bioactivity is dependent on the IL5 concentration as well as on the number of IL5RA present on the cell surface (a function of the cell type and culture conditions).

Interleukin 5 (IL-5) is a soluble T cell-derived factor, also known as T cell replacing factor (TRF), that induces B cell and eosinophil growth and differentiation. IL-5 exerts its biological activity through the IL-5 receptor (IL-5R), which is composed of two chains: an alpha chain that binds IL-5 with low affinity and a beta chain that does not bind IL-5, but together with the IL-5 alpha chain, constitutes the high affinity IL-5 receptor. The cytoplasmic domain of both the alpha and beta chains is essential for signal transduction. Specifically, the membrane-proximal proline-rich sequence of the cytoplasmic domain of the IL-5R receptor alpha subunit, IL-5Ralpha, is critical for the IL-5 induced proliferative response, expression of nuclear proto-oncogenes and tyrosine phosphorylation of cellular proteins, such as JAK1 and JAK2.